和黄医药(00013.HK):沃瑞沙和泰瑞沙联合疗法获中国批准用于治疗 触发阿斯利康1,100万美元里程碑付款
和黄医药(00013.HK)公布,沃瑞沙(ORPATHYS,赛沃替尼/savolitinib)和泰瑞沙(TAGRISSO,奥希替尼/osimertinib)的联合疗法的新药上市申请获国家药监局批准,用于治疗表皮生长因子受体(EGFR)基因突变阳性经EGFR酪氨酸激(酉每)抑制剂(TKI)治疗后进展的伴MET扩增的局部晚期或转移性非鳞状非小细胞肺癌患者。
沃瑞沙是一种强效、高选择性的口服MET TKI。泰瑞沙是一种不可逆的第三代EGFR TKI。此项批准将触发一项来自阿斯利康(AZN.US)的1,100万美元的里程碑付款,阿斯利康在中国同时负责沃瑞沙和泰瑞沙的销售。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.